The well-understanding in the regulation and mechanisms of distinct RAR subtypes is clinically significant for providing new insights into the combination of anti-carcinogenic action and regenerative therapy through the use of specific RAR subtype agonists or antagonists in patients with ESCC. This evidence concerns the gene RARA and esophageal squamous cell carcinoma.